Foundation Medicine Secures Z-Code ID as Test Sales Rise; Aims to Develop NGS-based CDx with Clovis | GenomeWeb

NEW YORK (GenomeWeb) – Foundation Medicine said last week that orders for its NGS-based tumor profiling tests — FoundationOne and FoundationOne Heme — continue to rise, both among the academic medical community as well as among community oncologists. It has also received unique identifiers for its tests from the online test registry McKesson Diagnostics Exchange, which it said would help in obtaining reimbursement for its tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.